Britain has incorporated health into its industrial strategy. In the fast-changing life sciences sector, a clear long-term plan, proactive analysis, and adaptability are essential for competitiveness. The government’s major investment in health data underpins this strategy.
To enhance strategic focus, the British government launched a ten-year Life Sciences Sector Plan last year. The plan leverages national research strengths to drive coordinated growth and health strategy, directly linking the National Health Service’s (NHS) future to the performance of its laboratories and manufacturing facilities.
The life sciences sector contributes approximately €115 billion annually to the UK economy and employs around 300,000 people, primarily outside London and in the South East. The sector prioritises exports. In 2024, medicines and medical technologies became the United Kingdom’s third-largest goods export by value. Private investment has grown in response. In 2023, the United Kingdom ranked third globally in life sciences equity financing, behind the United States and China.
To achieve these goals, the plan assigns greater responsibility to the sector, which must deliver two objectives from the broader Plan for Change: faster and more sustainable economic growth, and a stronger and prevention-focused NHS. In a country where long-term illness limits labour-market participation, improved health is both a social benefit and an economic necessity.
Three pillars, one goal The plan is structured around three pillars: world-class research, a highly competitive business environment, and an innovation-driven National Health Service.
The first pillar, Enabling World-Class R&D, builds on Britain’s established strengths in discovery science, from genomics to advanced therapeutics. To support this, the plan allocates over €2.3 billion in government funding during the current Spending Review period, supplemented by funding from UK Research and Innovation (UKRI) and the National Institute for Health and Care Research (NIHR).
The second pillar, Making the UK an Outstanding Place to Start, Scale and Invest, focuses on grants, regulatory reform, and attracting international investment. The third pillar, Driving Health Innovation and NHS Reform, positions the National Health Service as a platform for innovation rather than solely a cost centre. The NHS will open data, boost clinical research, and adopt new technologies, despite ongoing challenges.
“The government is making substantial investments in health data”
Money and machinery The government is making substantial investments in health data a central element of the plan. Up to €692 million will fund the new Health Data Research Service, supported by the Wellcome Trust and public sources. The service aims to enable secure and efficient use of NHS data for research and innovation while maintaining public trust. If successful, it could provide Britain with a significant advantage, as few countries have a single-payer health system with longitudinal records of this scale.
In addition to its focus on health data, the government prioritises domestic manufacturing growth. The Life Sciences Innovative Manufacturing Fund (LSIMF) will provide up to €600 million in capital grants to support the production of medicines, diagnostics, and medical technologies in Britain. The goal is to retain high-value manufacturing, strengthen supply chains, and create skilled jobs. Grants will target projects at risk of delay, downsizing, or relocation overseas.
To further support these initiatives, the government will reform regulations to address longstanding industry concerns. The Medicines and Healthcare Products Regulatory Agency (MHRA) will receive additional investment to accelerate product approvals. They will also improve coordination with the National Institute for Health and Care Excellence (NICE) on market access for medical technology. The government has also committed to reducing regulatory costs by 25 per cent.
Six flagship promises:
- The first flagship promise supports the data and research pillar. The Health Data Research Service aims to “unlock NHS data to find new cures” by developing an AI-ready platform for researchers and companies.
- For clinical trials, the government will reduce administrative barriers by streamlining approvals and integrating research into NHS care, allowing patients to join trials sooner.
- The Life Sciences Innovative Manufacturing Fund will support British manufacturing by providing grants for new and expanded biologics and diagnostics production facilities.
- The fourth promise addresses the regulatory environment. Additional resources for the Medicines and Healthcare Products Regulatory Agency will accelerate patient access to new treatments by streamlining and clarifying regulatory processes, supporting both innovation and business competitiveness.
- The fifth promise advances National Health Service innovation. The proposed NHS passport will accelerate adoption of proven tools across the NHS by providing streamlined access to AI-enabled cancer imaging and wearables.
- The government will support leading UK firms by establishing at least one major industry partnership each year, directly linking these partnerships to efforts to retain promising companies in the United Kingdom.
While these flagship promises have the potential to set a new direction, several build on existing initiatives. Investments have already begun, including up to €710 million for the data service, about €770 million for Genomics England, and up to €420 million for Our Future Health, a large population health cohort. “Innovator passports” to accelerate the adoption of new technologies in the National Health Service are already being implemented.
Officials emphasise that the plan was developed collaboratively, not in departmental isolation. Over 250 organisations, including clinicians, scientists, NHS executives, and industry groups, contributed. The plan aligns with the ten-year Health Plan for England and the broader Industrial Strategy. The aim is to avoid the common pitfalls of Whitehall fragmentation. Building on this collaborative approach, the plan’s structure further enhances accountability and clarity.
Each action includes designated leads and clear goals, making progress easier to monitor and ensuring accountability. The emphasis is on delivery rather than aspiration, marking a notable shift in a country known for many polished but unfulfilled innovation strategies.
“Life sciences are a cornerstone of the British economy”
AI: Promise and pressure The plan makes significant investments in artificial intelligence, which is transforming research, diagnostics, treatment, and manufacturing. Britain aims to capitalise on this trend. McKinsey’s Global Institute estimates potential annual AI gains in the pharmaceutical and medical products sector at €52–96 billion. With established strengths in machine learning and biomedical data science, the United Kingdom seeks to capture a substantial share of these gains. However, this opportunity also brings challenges that require careful management, especially in healthcare implementation.
Beyond these opportunities and challenges, AI in healthcare raises important questions. AI models require extensive, high-quality datasets, which the NHS holds. National use of patient data requires strong governance, genuine consent, and robust safeguards. Previous data-sharing initiatives failed due to public scepticism. The Health Data Research Service will succeed only if it earns political trust and demonstrates technical expertise.
A crown jewel under pressure Life sciences are a cornerstone of the British economy, driving innovation and accounting for 17 per cent of UK business R&D spending, the largest share of any sector. The sector supports the government’s aims to create quality jobs and lead in science. However, intensified global competition is pressuring this sector as major regions launch investment initiatives. The United Kingdom is responding by positioning itself to remain a top destination for life sciences capital and talent.
This pressure is growing as global competition intensifies. America is enacting the Inflation Reduction Act and the CHIPS (Creating Helpful Incentives to Produce Semiconductors) and Science Act. Europe is working to strengthen health system resilience. Asia is expanding its manufacturing. All are seeking investment that once may have gone to Britain. The United Kingdom is attempting to stay in the top tier of destinations for life sciences capital and talent.
Risks of over-promising Many industrial strategies fail to bridge the gap between ambition and delivery. Reducing regulatory costs is easy to promise, but upholding standards is more challenging. Streamlining clinical trials sounds compelling, yet trials depend on an already stretched NHS workforce. Transforming the health service into a research engine is not achievable through policy changes alone. Decisive changes to incentives, infrastructure, and culture are essential.
Anchoring manufacturing domestically will increase costs compared to global supply chains, especially if support schemes lack precision. The Life Sciences Innovative Manufacturing Fund is designed to safeguard projects genuinely at risk of relocation. However, distinguishing real threats from lobbying remains challenging.
Health as an industrial strategy The government aims to unify health and industry to grow the economy by improving public health and expanding the life sciences sector. If successful, Britain will export more drugs, devices, and its unique model of integrating scientific strength, a national health system, and industrial drive. However, this integration also carries risks. The strategy is based on the belief that science can drive national renewal. Its success will depend more on political commitment and effective administration over the next decade than on vision alone.
